The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 23, 2013
Filed:
May. 06, 2009
Peter A. Blomgren, North Branford, CT (US);
David R. Brittelli, Branford, CT (US);
Kevin S. Currie, North Branford, CT (US);
Seung H. Lee, Branford, CT (US);
Jeffrey E. Kropf, Branford, CT (US);
Scott A. Mitchell, East Haven, CT (US);
Aaron C. Schmitt, Hamden, CT (US);
Xiaojing Wang, Foster City, CA (US);
Jianjun Xu, Madison, CT (US);
Zhongdong Zhao, Guilford, CT (US);
Pavel E. Zhichkin, Delmar, NY (US);
Peter A. Blomgren, North Branford, CT (US);
David R. Brittelli, Branford, CT (US);
Kevin S. Currie, North Branford, CT (US);
Seung H. Lee, Branford, CT (US);
Jeffrey E. Kropf, Branford, CT (US);
Scott A. Mitchell, East Haven, CT (US);
Aaron C. Schmitt, Hamden, CT (US);
Xiaojing Wang, Foster City, CA (US);
Jianjun Xu, Madison, CT (US);
Zhongdong Zhao, Guilford, CT (US);
Pavel E. Zhichkin, Delmar, NY (US);
CGI Pharmaceuticals, Inc., Branford, CT (US);
Genentech, Inc., South San Francisco, CA (US);
Abstract
The invention relates to compounds of the following Formula I wherein R, R, Z, W, and D are defined herein, that inhibit Btk and therefore are useful in the treatment of diseases responsive to inhibition of Btk activity such as cancer. The invention also relates to pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, as well as methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described, and methods for determining the presence of Btk in a sample.